EP3496754A4 - Wirksamkeit von anti-hla-dr-antikörper-arzneimittelkonjugat im?-140 (hl243-cl2a-sn-38) in hla-dr-positiven krebserkrankungen - Google Patents

Wirksamkeit von anti-hla-dr-antikörper-arzneimittelkonjugat im?-140 (hl243-cl2a-sn-38) in hla-dr-positiven krebserkrankungen Download PDF

Info

Publication number
EP3496754A4
EP3496754A4 EP17840061.0A EP17840061A EP3496754A4 EP 3496754 A4 EP3496754 A4 EP 3496754A4 EP 17840061 A EP17840061 A EP 17840061A EP 3496754 A4 EP3496754 A4 EP 3496754A4
Authority
EP
European Patent Office
Prior art keywords
hla
cl2a
efficacy
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17840061.0A
Other languages
English (en)
French (fr)
Other versions
EP3496754A1 (de
Inventor
Serengulam V. Govindan
Thomas M. Cardillo
David M. Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/281,453 external-priority patent/US10130626B2/en
Priority claimed from US15/484,308 external-priority patent/US10058621B2/en
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of EP3496754A1 publication Critical patent/EP3496754A1/de
Publication of EP3496754A4 publication Critical patent/EP3496754A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP17840061.0A 2016-08-11 2017-08-04 Wirksamkeit von anti-hla-dr-antikörper-arzneimittelkonjugat im?-140 (hl243-cl2a-sn-38) in hla-dr-positiven krebserkrankungen Withdrawn EP3496754A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662373591P 2016-08-11 2016-08-11
US15/281,453 US10130626B2 (en) 2012-12-13 2016-09-30 Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US201662428231P 2016-11-30 2016-11-30
US15/484,308 US10058621B2 (en) 2015-06-25 2017-04-11 Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
PCT/US2017/045516 WO2018031408A1 (en) 2016-08-11 2017-08-04 EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS

Publications (2)

Publication Number Publication Date
EP3496754A1 EP3496754A1 (de) 2019-06-19
EP3496754A4 true EP3496754A4 (de) 2020-04-15

Family

ID=61163070

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17840061.0A Withdrawn EP3496754A4 (de) 2016-08-11 2017-08-04 Wirksamkeit von anti-hla-dr-antikörper-arzneimittelkonjugat im?-140 (hl243-cl2a-sn-38) in hla-dr-positiven krebserkrankungen

Country Status (4)

Country Link
EP (1) EP3496754A4 (de)
CN (1) CN109562172B (de)
CA (1) CA3031737A1 (de)
WO (1) WO2018031408A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10799597B2 (en) * 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
FR3072880A1 (fr) * 2017-10-30 2019-05-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Formulation liposomale et son utilisation en therapie anti-tumorale
TW202003047A (zh) * 2018-03-23 2020-01-16 美商西雅圖遺傳學公司 包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
AU2020297587B2 (en) 2019-06-21 2026-03-19 Pattern Computer, Inc. Therapeutic compositions and methods for treating cancers
CN116916939A (zh) * 2020-12-12 2023-10-20 Io医药股份有限公司 碘递送化合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054622A1 (en) * 2002-12-13 2004-07-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20130078263A1 (en) * 2011-09-22 2013-03-28 Immunomedics, Inc. Anti-HLA-DR Antibodies Suppress Allogeneic and Xenogeneic Immune Responses to Organ Transplants
US20140170063A1 (en) * 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity
US20140227178A1 (en) * 2005-03-03 2014-08-14 Immunomedics, Inc. Humanized Anti-HLA-DR Antibodies
US20140227180A1 (en) * 2012-12-13 2014-08-14 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2550975A1 (de) * 2011-07-29 2013-01-30 Sanofi Kombinationstherapie zur Behandlung von CD19+B-Zellen-Malignomsymptomen mit einem Anti-CD19-Maytansinoidimmunkonjugat und Rituximab
AU2014293670B2 (en) * 2013-07-23 2019-08-01 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054622A1 (en) * 2002-12-13 2004-07-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20140227178A1 (en) * 2005-03-03 2014-08-14 Immunomedics, Inc. Humanized Anti-HLA-DR Antibodies
US20130078263A1 (en) * 2011-09-22 2013-03-28 Immunomedics, Inc. Anti-HLA-DR Antibodies Suppress Allogeneic and Xenogeneic Immune Responses to Organ Transplants
WO2013043800A1 (en) * 2011-09-22 2013-03-28 Immunomedics, Inc. Anti-hla-dr antibodies suppress allogeneic and xenogeneic immune responses to organ transplants
US20140170063A1 (en) * 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity
US20140227180A1 (en) * 2012-12-13 2014-08-14 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US20150196662A1 (en) * 2012-12-13 2015-07-16 Immunomedics, Inc. Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THOMAS M. CARDILLO ET AL: "IMMU-140, a Novel SN-38 Antibody-Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma", MOLECULAR CANCER THERAPEUTICS, vol. 17, no. 1, 1 January 2018 (2018-01-01), US, pages 150 - 160, XP055674397, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-17-0354 *

Also Published As

Publication number Publication date
CA3031737A1 (en) 2018-02-15
CN109562172B (zh) 2022-08-16
CN109562172A (zh) 2019-04-02
EP3496754A1 (de) 2019-06-19
WO2018031408A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
EP3431105A4 (de) Medizinische zusammensetzung zur behandlung von krebs
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
EP3436002A4 (de) Pharmazeutische kombinationen zur behandlung von krebs
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
EP3494142A4 (de) Anti-siglec-7-antikörper zur behandlung von krebs
GEAP202115055A (en) Anti-cd27 antibodies
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
EA201890006A1 (ru) Применение экзосом для лечения болезни
EP3393475C0 (de) Ciforadent alleine oder in kobmination with atezolizumab zur verwendung bei der behandlung von krebs
ME03772B (de) Axl-spezifische antikörper-wirkstoff-konjugate zur krebsbehandlung
EP3400013A4 (de) Cadherin-17-spezifische antikörper und zytotoxische zellen zur krebsbehandlung
MX389684B (es) Anticuerpos anti tigit.
EP3524267A4 (de) Therapie für arzneimittelresistenten krebs durch verabreichung von anti-her2-antikörper/arzneimittel-konjugat
EP3474854A4 (de) Krebsbehandlungskombinationen
EP3496754A4 (de) Wirksamkeit von anti-hla-dr-antikörper-arzneimittelkonjugat im?-140 (hl243-cl2a-sn-38) in hla-dr-positiven krebserkrankungen
EP2978446A4 (de) Verfahren und mittel zur behandlung von morbus alzheimer
EP3490548A4 (de) Verabreichung von hypoxieaktivierten prodrugs in kombination mit immunmodulatoren zur behandlung von krebs
EP3762032A4 (de) Antikörper-arzneimittel-konjugate gegen den gewebefaktor und deren verwendung in der behandlung von krebs
EP3443962A4 (de) Chinolinderivat zur behandlung von magenkrebs
MA47111A (fr) Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
EP3347010A4 (de) Synthese und zusammensetzung von photodynamischen therapeutischen mitteln zur gezielten behandlung von krebs
CY1127309T1 (el) Ebselen για χρηση στη θεραπεια της νοσου meniep

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190307

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039395000

Ipc: A61K0047680000

A4 Supplementary search report drawn up and despatched

Effective date: 20200318

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20200312BHEP

Ipc: A61K 39/395 20060101ALI20200312BHEP

Ipc: A61K 47/68 20170101AFI20200312BHEP

Ipc: C07K 16/30 20060101ALI20200312BHEP

Ipc: A61P 35/02 20060101ALI20200312BHEP

Ipc: A61P 35/04 20060101ALI20200312BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230921

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20240202